ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CSTL Castle Biosciences Inc

21.48
-0.68 (-3.07%)
Last Updated: 16:23:54
Delayed by 15 minutes
Share Name Share Symbol Market Type
Castle Biosciences Inc NASDAQ:CSTL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.68 -3.07% 21.48 21.47 21.55 22.36 21.1401 22.10 52,369 16:23:54

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

15/05/2024 12:00pm

Business Wire


Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Castle Biosciences Charts.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact: Camilla Zuckero czuckero@castlebiosciences.com

Media Contact: Allison Marshall amarshall@castlebiosciences.com

1 Year Castle Biosciences Chart

1 Year Castle Biosciences Chart

1 Month Castle Biosciences Chart

1 Month Castle Biosciences Chart